Lyme neuroborreliosis, the neurological manifestation of Lyme disease, presents a formidable diagnostic challenge in children. Its symptoms—facial nerve palsy, severe headache, meningeal signs—are non-specific and overlap with numerous other inflammatory and infectious conditions of the central nervous system. Conventional diagnosis relies on detecting anti-Borrelia antibodies in serum and cerebrospinal fluid alongside pleocytosis, an elevated white cell count in the spinal fluid. Yet serological assays have limited sensitivity early in infection, and children appear to be disproportionately affected, likely because of greater outdoor exposure and the particular characteristics of their developing immune systems. Metabolomics, the systematic measurement of small molecules, offers something serology cannot: a direct, real-time snapshot of the biochemical alterations occurring inside the central nervous system as the infection unfolds.

The Polish team enrolled 20 children with confirmed Lyme neuroborreliosis and 20 healthy age-matched controls, all recruited from the Lower Silesian Voivodeship. The patients, aged 6 to 17, had a median symptom duration of ten days before admission, and crucially, all were treatment-naïve—none had received antibiotics before sampling. This detail matters enormously for metabolomics, since even a short course of antimicrobial therapy can distort the metabolic landscape. From each patient, the researchers collected paired serum and cerebrospinal fluid samples simultaneously, before any treatment began, allowing a rare within-patient comparison between the systemic circulation and the central compartment. The study was approved by the institutional ethics committee and conducted in accordance with the Declaration of Helsinki, with informed consent obtained from all legal guardians.

The analytical approach was deliberately comprehensive. The team employed both nuclear magnetic resonance spectroscopy on a 600 MHz instrument and untargeted liquid chromatography-tandem mass spectrometry coupled to a quadrupole time-of-flight mass spectrometer. To maximize coverage of the CSF metabolome, every spinal fluid sample was run through two complementary chromatographic columns—one based on BEH Amide chemistry and the other on a zwitterionic ZIC-pHILIC stationary phase—generating two distinct datasets from the same twenty patients. Quality control samples, prepared by pooling aliquots from all extracts, were injected periodically throughout the analytical sequences to monitor instrument stability. In the NMR analysis, chemical shift reproducibility was exceptional, with coefficients of variation below 1% for 25 of the 27 annotated biomolecules, a result that validates the peak assignment strategy and confirms that the observed differences reflect genuine pathophysiology rather than instrumental noise.

Handling the data required considerable statistical care. Missing values in metabolomics datasets are typically “missing not at random,” arising because metabolite concentrations fall below the limit of detection rather than through random technical failure. The researchers compared several imputation approaches—including half-minimum, k-nearest neighbors, and quantile regression imputation of left-censored data—and found that a Random Forest algorithm consistently performed best, yielding the lowest normalized root mean square error and the optimal sum-of-ranks metric. After imputation and log2 transformation, the data were normalized using probabilistic quotient normalization, with quality control samples incorporated into the construction of the reference spectrum, then mean-centered and Pareto-scaled before statistical modeling.

The results were striking. In the serum, univariate analysis identified 17 significantly altered metabolites, and the most consistent finding was profound dysregulation of the purine pathway. Hypoxanthine, xanthine, and uric acid were all markedly elevated in the children with neuroborreliosis, with uric acid showing one of the largest fold changes in the entire dataset. This pattern admits at least two interpretations. On one hand, elevated purines may simply reflect the non-specific consequences of infection: increased cellular turnover, tissue injury, inflammatory activation, and oxidative stress. On the other hand, the researchers point to a more intriguing possibility grounded in Borrelia biology. The spirochete lacks a de novo purine synthesis pathway entirely and must salvage purines from its host to build its own nucleic acids. Mouse studies have shown that Borrelia burgdorferi depends on host-derived hypoxanthine for survival and infection, and evidence links purine regulation to bacterial resistance against reactive oxygen species. The authors are careful to note that their untargeted data cannot establish causality, and the purine elevation may combine both host and pathogen-driven contributions.

Equally significant was the elevation of L-tyrosine in the patients’ serum, which displayed the highest statistical significance among all metabolites measured, with a false discovery rate far below conventional thresholds. The researchers hypothesize that this mirrors the activation of tyrosine-dependent signaling cascades during acute inflammation, a mechanism previously implicated in the inflammatory damage that Borrelia inflicts on oligodendrocytes, the myelin-producing cells of the nervous system. Pathway enrichment analysis, mapping significant metabolites onto the KEGG database, repeatedly flagged the biosynthesis of phenylalanine, tyrosine, and tryptophan, alongside purine metabolism and glycerophospholipid metabolism. Notably, these enriched pathways appeared consistently across both blood and cerebrospinal fluid samples and across both statistical approaches, indicating a reproducible signal independent of analytical method.

The cerebrospinal fluid analysis told its own compelling story. Unsupervised hierarchical clustering of the 68 metabolites consistently detected across all 20 CSF samples revealed that most patients formed a broad, heterogeneous cluster, but three individuals branched off at the earliest node of the dendrogram, exhibiting a pronounced, coordinated up-accumulation of a large block of co-regulated metabolites. This group included amino acids such as glutamate, tyrosine, and phenylalanine; methylated osmolytes including choline, betaine, and asymmetric dimethylarginine; and purine intermediates including xanthine and uric acid. Several of these compounds overlapped with the metabolites altered in serum, suggesting that these three children may harbor a more pronounced systemic-to-central metabolic disturbance, and pointing toward greater permeability of the blood-CSF barrier in these individuals. Changes in glycerophospholipid metabolism—the chemical family that includes the membrane components phospholipids—further hint at transient disruption of the blood-brain barrier during active neuroinfection, although the authors caution that confirming structural damage requires complementary imaging or biophysical evidence.

Within the CSF, choline and glutamate emerged as candidate signatures of particular interest. Choline contributed strongly to group discrimination in the supervised PLS-DA models, with a variable importance in projection score exceeding 1.75. Elevated choline has previously been associated with active neuroinflammation and cellular membrane turnover, and it participates in epigenetic regulation as a methyl-group donor, mechanisms that may modulate inflammatory and oxidative stress responses. Supporting this interpretation, magnetic resonance spectroscopy studies of neuroborreliosis patients have independently identified choline abnormalities. Glutamate, the brain’s principal excitatory neurotransmitter, presents a different concern: its accumulation in the spinal fluid could theoretically precipitate excitotoxic cascades, a process in which excessive neurotransmitter signaling damages neurons. Both findings, the researchers emphasize, remain hypotheses requiring validation, particularly because the study lacked a non-Lyme neuroinflammatory control group that would establish whether these shifts are specific to Borrelia infection or represent a generalized central nervous system response to inflammation.

The study also connects to the broader tryptophan-kynurenine story in neuroborreliosis. Although tryptophan and kynurenine were not directly quantified in the CSF in this cohort, the enriched pathways indirectly suggest a metabolic shift consistent with activation of this pathway, which is driven by interferon-gamma-induced indoleamine 2,3-dioxygenase. Previous work has shown that children with Lyme disease display elevated CSF kynurenine and kynurenic acid, and the kynurenine-to-tryptophan ratio has been proposed as a tool for distinguishing bacterial from viral central nervous system infections. The authors also speculate that elevated uric acid, beyond being a purine catabolite, may function as a damage-associated molecular pattern, activating NLRP3 inflammasome complexes and amplifying local inflammation—a speculative metabolic synergy in which purine and tryptophan metabolites co-modulate the immunometabolic landscape.

As a pilot study, the work carries clear limitations, most notably the absence of matched CSF controls, which forced the researchers to draw conclusions about the central nervous system primarily through multivariate statistics and the identification of internal subgroups within the patient population. Yet the simultaneous collection of paired serum and CSF samples is a genuine methodological strength, enabling direct within-patient comparison between the systemic and central compartments. The robustness of the supervised models was verified through permutation testing with 1,000 random label permutations, achieving balanced error rates of zero with empirical permutation p-values below 0.001, indicating that the observed separation between patients and controls was unlikely to have arisen by chance.

What emerges from this study is a coherent immunometabolic narrative of pediatric neuroborreliosis: a pathogen that scavenges host purines, an inflammatory response generating oxidative stress and purine catabolites, aromatic amino acid shifts signaling receptor-level immune activation, membrane lipid changes suggesting barrier compromise, and choline and glutamate elevations pointing toward neuroinflammation and potential excitotoxicity. The identified signatures—particularly those governing purine metabolism and the inferred kynurenine pathway—now constitute a promising foundation for larger, controlled biomarker discovery studies. For a disease whose pediatric presentation is frequently nonspecific and whose standard tests often fall short, the prospect of a metabolomics-based diagnostic that reads the biochemical conversation between Borrelia and the developing brain is a compelling one, and this pilot study provides the detailed map from which such a test could eventually be built.

Pancreatic ductal adenocarcinoma is notoriously lethal, with late-stage diagnosis occurring in roughly 80% of cases and an alarmingly low five-year survival rate of just 13.7%. One of the cornerstones in managing PDAC has been the measurement of CA19-9 levels, which typically correlate with disease stage and patient prognosis. Elevated CA19-9 concentrations conventionally signal advanced disease and a poorer outlook, whereas levels below 37 units per milliliter are interpreted as normal or indicative of lower-risk disease following diagnosis.

However, clinical experience has repeatedly demonstrated that this biomarker is not universally reliable. Approximately a tenth of pancreatic cancer patients do not exhibit elevated CA19-9 levels regardless of tumor burden. This anomaly stems from a genetic determinant known as the Lewis antigen status, specifically related to polymorphisms in the FUT3 gene that impair the activity of fucosyltransferase enzymes necessary for synthesizing CA19-9. These patients, referred to as CA19-9 “nonproducers,” present a vexing diagnostic quandary as their low serum levels belie the severity of their disease.

The research team, led by Dr. Yung-Yeh Su from the National Health Research Institutes in Taiwan, embarked on a comprehensive analysis to disentangle this confounding factor. Utilizing whole-exome sequencing, they genotyped FUT2 and FUT3 variants in a cohort of 615 PDAC patients treated at Taiwanese medical centers, stratifying individuals into groups based on the extent of fucosyltransferase functionality. This stratification ranged from FUT3-null genotypes—corresponding to nonproducers and Lewis antigen negativity—to high FUT activity.

Employing half the patient cohort as a training set, the team focused on identifying a CA19-9 threshold that would effectively signal Lewis antigen-negative status absent the need for genetic testing. Their rigorous analysis revealed that a CA19-9 cutoff of 7 units/mL or less accurately identifies patients with the Lewis antigen-negative genotype. This newly defined threshold demonstrated an impressive 87.9% accuracy in subsequent validation, marking a significant improvement over the conventional <37 units/mL benchmark which fails to differentiate between low-tumor burden and genetic nonproduction.

Perhaps most striking are the clinical implications borne out by survival data. Lewis antigen-negative patients with CA19-9 levels ≤7 units/mL exhibited overall survival rates remarkably similar to those with exceedingly high CA19-9 (>200 units/mL), both groups reflecting poor prognoses. Median overall survival in the ≤7 units/mL group was just 13.5 months, juxtaposed with 12.8 months in the high CA19-9 stratum, highlighting that low CA19-9 does not equate to benign disease in these individuals.

In striking contrast, patients with intermediate CA19-9 levels—from 7 to 37 units/mL and from 37 to 200 units/mL—demonstrated the most favorable outcomes, with median survival exceeding 22 months. This biphasic survival pattern elucidates the complex interplay between tumor biology and biomarker expression. The findings decisively refute the prevailing notion that CA19-9 values under 37 units/mL uniformly indicate low risk.

Recognizing the practical limitations of routine FUT genotyping in clinical workflows, the researchers advocate for integrating the 7 units/mL cutoff into a dual-threshold CA19-9 scoring system. This approach serves as a pragmatic surrogate for identifying high-risk Lewis antigen-negative patients, enabling clinicians to recalibrate prognosis and tailor therapeutic strategies more accurately. Hence, CA19-9 levels below this refined cutoff should prompt heightened clinical vigilance rather than reassurance.

Dr. Su emphasizes that this research redefines the interpretation of CA19-9, a biomarker long entrenched in pancreatic cancer management. “The conventional normal range of less than 37 units/mL masks a high-risk subgroup. Our dual-threshold model uncovers these patients, bridging a critical gap,” he asserts. This paradigm shift holds promise to enhance patient outcomes by preventing the pitfalls of underdiagnosis and allowing for more nuanced risk stratification.

While the study’s strengths lie in its robust genotypic methodology and large, well-characterized cohort, the authors acknowledge certain limitations. Primary among these is the geographic and ethnic homogeneity of the sample, with all participants drawn from Taiwan. This raises questions about the generalizability of the dual-threshold model across diverse populations where genetic backgrounds and CA19-9 assay standardization may vary. Additionally, interlaboratory differences in CA19-9 measurements could introduce variability, underscoring the need for harmonized testing methods.

Reflecting this caution, the researchers propose an international multicenter validation study as a pivotal next step. Such research would ascertain the model’s efficacy across broader demographics and clinical contexts, potentially establishing a new global standard for CA19-9 interpretation in pancreatic adenocarcinoma.

This study’s ramifications extend beyond clinical practice to the scientific understanding of tumor biomarkers. It highlights the intricate genetic regulatory mechanisms influencing biomarker expression and reinforces the necessity of integrating genomics into diagnostic algorithms. As personalized medicine continues to evolve, such nuanced frameworks will be indispensable.

Funding support from Taiwanese Ministry of Science and Technology, National Health Research Institutes, and other prominent institutions underscores the national commitment to combating pancreatic cancer’s deadly toll. Notably, Dr. Su reports no conflicts of interest, bolstering confidence in the objectivity of the findings.

In conclusion, this innovative research not only redefines CA19-9 cutoffs but also exemplifies the transformative power of integrating genetic insights into biomarker analysis. The dual-threshold CA19-9 model promises to revolutionize risk assessment in pancreatic cancer, identifying an elusive high-risk subset previously masked by conventional testing. As this knowledge disseminates and undergoes further validation, it could markedly enhance early detection, treatment planning, and ultimately patient survival in one of oncology’s most formidable adversaries.

Subject of Research: Pancreatic ductal adenocarcinoma, CA19-9 biomarker, Lewis antigen status, genetic polymorphisms, prognostic stratification

Article Title: A New CA19-9 Cut-Off Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDAC

News Publication Date: 21-May-2026

Web References:

• Clinical Cancer Research Journal
• DOI: 10.1158/1078-0432.CCR-25-4564

Keywords: Pancreatic cancer, CA19-9, Lewis antigen-negative, FUT3 polymorphism, biomarker stratification, prognostic cutoff, PDAC, tumor markers, survival analysis, genetic polymorphism, fucosyltransferase, personalized oncology